NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors

Tyrosine kinase domains dynamically fluctuate between two main structural forms that are referred to as type I (DFG-in) or type II (DFG-out) conformations. Comprehensive data comparing type I and type II inhibitors are currently lacking for NTRK fusion-driven cancers. Here we used a type II NTRK inhibitor, altiratinib, as a model compound to investigate its inhibitory potential for larotrectinib (type I inhibitor)-resistant mutations in NTRK. Our study shows that a subset of larotrectinib-resistant NTRK1 mutations (V573M, F589L and G667C) retains sensitivity to altiratinib, while the NTRK1V573M and xDFG motif NTRK1G667C mutations are highly sensitive to type II inhibitors, including altiratinib, cabozantinib and foretinib. Moreover, molecular modeling suggests that the introduction of a sulfur moiety in the binding pocket, via methionine or cysteine substitutions, specifically renders the mutant kinase hypersensitive to type II inhibitors. Future precision treatment strategies may benefit from selective targeting of these kinase mutants based on our findings.


Reporting Summary
Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, seeAuthors & Referees and theEditorial Policy Checklist .

Statistics
For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a Confirmed The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly The statistical test(s) used AND whether they are one-or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Give P values as exact values whenever suitable.

For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated Our web collection on statistics for biologists contains articles on many of the points above.

Software and code
Policy information about availability of computer code Data collection

Data analysis
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.

Data
Policy information about availability of data All manuscripts must include a data availability statement. This statement should provide the following information, where applicable: -Accession codes, unique identifiers, or web links for publicly available datasets -A list of figures that have associated raw data -A description of any restrictions on data availability Field-specific reporting Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection. Homology modeling and inhibitor docking studies were conducted using the YASARA software, and homology models were verified using PROCHECK module of PDBSum server.
The following commercially available software was used for data analysis and representation: Microsoft Excel, GraphPad Prism, ImageLab Software (BIO-RAD), Adobe Photoshop and Adobe Illustrator The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

October 2018
For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf

Life sciences study design
All studies must disclose on these points even when the disclosure is negative. For animal studies, 5 mice per group was planned as this design has allowed us to reliably detect differences of 25% or more between groups over the many years that we have performed animal work. In one instance we had 4 mice per group as not all tumors grew and an ethical decision was made to proceed with the smaller sample size instead of sacrificing the mice and starting all over again. For in vitro viability studies there were at least 3 replicates of each condition in three to five independent experiments, unless in case of rare exception due to technical or COVID-19 related experimental bandwidth reasons as noted.
No data was excluded from any analysis.
All in vitro dose-response cell viability experiments included a minimum of three independent replicates in each experiment, and the experiment was repeated at least three and up to five times. All data were highly consistent, and either one representative experiment or an average of all independent experiments was chosen for illustration in the figures.
For animal studies tumor bearing mice were assigned to groups so the average tumor volume of each group at start of treatment was similar.
No blinding was used in data collection or analysis. All data collected were in specific categories and were quantitative. No data was collected and analyzed by the same person.
All antibodies used for Western blotting were obtained from either Cell Signaling Technology or In vitrogen and have been used extensively in published literature. Antibodies used for IHC were obtained from Abcam, Dako or Leica Biosystems, and these antibodies have been validated and routinely used for clinical diagnosis at MSKCC and many other institutions. The catalog number of each antibody and specificity is listed in Supplementary Methods.
Positive controls that are used on clinical diagnosis were included on IHC studies. All Western blotting antibodies were validated by the commercial provider and data confirmed in many publications by independent research groups over many years.
Original Ba/F3 cells were procured from DSMZ (Catalog # ACC 300). The cells have existed in the laboratory for some time now. HEK293A cells were used for transient transfection. These were originally procured from Thermo Scientific (Catalog # R70507), and have been sub-cultivated in the laboratory for several years now. Platinum-E (Plat-E) Retroviral Packaging Cell Line was purchased from Cell BioLabs, Inc.
Ba/F3 cells are exquisitely dependent on the cytokine IL-3. All experiments involve the requisite control of IL-3 withdrawal to ensure reproducible Ba/F3 cell death in 96 hours. HEK293A and Platinum-E cells were not authenticated as they were only used transiently for expressing protein or generating retrovirus.
Cell lines were tested for mycoplasma once every 3 months. One incidence of mycoplasma contamination occurred with four Ba/F3 stable cell lines. At this point, these cells were treated for anti-mycoplasma antibiotics for three consecutive weeks, and retested after antibiotic washout for one week. The cells were cleared and responded to inhibitors no differently after treatment with anti-mycobacterial reagent. Note that full information on the approval of the study protocol must also be provided in the manuscript.

Human research participants
Policy information about studies involving human research participants Population characteristics

Recruitment
Ethics oversight Note that full information on the approval of the study protocol must also be provided in the manuscript.

Clinical data Policy information about clinical studies
All manuscripts should comply with the ICMJEguidelines for publication of clinical research and a completedCONSORT checklist must be included with all submissions.

Clinical trial registration
Study protocol

Data collection
Outcomes ChIP-seq

Data deposition
Confirm that both raw and final processed data have been deposited in a public database such as GEO.
Confirm that you have deposited or provided access to graph files (e.g. BED files) for the called peaks.

Data access links
May remain private before publication.

Files in database submission
Genome browser session (e.g. UCSC) None.

Not relevant to this study
Not relevant to this study Not relevant to this study All studies were conducted in Nod Scid gamma (NSG) strain mice. All animals were female and used at 6 weeks of age.
This study did no involve wild animals.
This study does not include samples collected in the field. Flow cytometry was only used to enrich the NTRK-fusion expressing population before IL-3 withdrawal to make a stable cell line. The retroviral vector contains mCherry and this served as a surrogate marker for retroviral integration. Other than use flow cytometry to enrich the mCherry expressing cells, we did not perform any quantitative flow cytometry, and do not think the questions are highly relevant to this use case. Particularly because the more rigorous step in creating a stable Ba/F3 NTRK-fusion cell line is the IL-3 withdrawal step, where any cell that has sub-threshold or no NTRK-fusion expression underwent cell death and the remaining surviving cell population (minus IL-3) was considered the stable cell line.
Identify the instrument used for data collection, specifying make and model number.
Describe the software used to collect and analyze the flow cytometry data. For custom code that has been deposited into a community repository, provide accession details.
Describe the abundance of the relevant cell populations within post-sort fractions, providing details on the purity of the samples and how it was determined.
Describe the gating strategy used for all relevant experiments, specifying the preliminary FSC/SSC gates of the starting cell population, indicating where boundaries between "positive" and "negative" staining cell populations are defined.